(Reuters) - Japan’s No.4 drug maker Eisai Co Ltd (4523.T) expects sales to stay slack over the next five years after the loss of U.S. patent protection for Aricept, its top-selling Alzheimer’s drug, leading it to cut jobs. Eisai is targeting sales of over 800 billion yen ($9.77 billion) in the year starting in April 2015, only slightly higher than an estimated 770 billion yen for the year ending on March 31, it said in a medium-term strategic plan on Thursday.
